StockNews.AI
ASRT
StockNews.AI
21 days

SPECTRUM PHARMACEUTICALS (NASDAQ: SPPI) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Class Action by September 24, 2025

1. Spectrum Pharmaceuticals faces securities fraud claims from investors. 2. The lawsuit concerns misleading statements about its clinical trial results. 3. Spectrum's shares were delisted due to its merger with Assertio Holdings. 4. Investors have until September 24, 2025, to join as lead plaintiffs. 5. These developments might impact ASRT's market perception and valuation indirectly.

11m saved
Insight
Article

FAQ

Why Bearish?

The ongoing litigation against Spectrum could create uncertainty for ASRT following the merger, similar to historical cases of stock price decline after mergers troubled by legal concerns.

How important is it?

Concerns regarding Spectrum could reflect negatively on ASRT due to their recent merger, impacting investor confidence.

Why Short Term?

Short-term implications are likely as news could lead to immediate investor reactions before effects stabilize.

Related Companies

SPPI

PHILADELPHIA, Sept. 8, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the "Class Period").

Investor Deadline: Investors who purchased or acquired Spectrum securities during the Class Period may, no later than September 24, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.

Spectrum is a biopharmaceutical company focused on oncology treatments.

The class action lawsuit alleges that Spectrum made false or misleading statements to investors regarding its Pinnacle Study, a clinical trial involving poziotinib, a drug intended to treat certain lung cancer patients.

Spectrum shares were delisted following the Company's merger with Assertio Holdings, Inc. (NASDAQ:ASRT).

If you are a Spectrum investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.

About Berger Montague

Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

For more information or to discuss your rights, please contact:

Andrew Abramowitz, Senior Counsel

Berger Montague

(215) 875-3015

aabramowitz@bergermontague.com

Caitlin Adorni

Berger Montague

(267) 764-4865

cadorni@bergermontague.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/spectrum-pharmaceuticals-nasdaq-sppi-class-action-deadline-approaching-berger-montague-advises-investors-to-inquire-about-a-securities-class-action-by-september-24-2025-302549845.html

SOURCE Berger Montague

Related News